News headlines about Veru (NASDAQ:VERU) have trended somewhat positive this week, according to Accern. The research group identifies positive and negative press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Veru earned a news sentiment score of 0.13 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 45.6221011145914 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Here are some of the news articles that may have impacted Accern Sentiment Analysis’s analysis:

VERU has been the subject of several research analyst reports. Zacks Investment Research upgraded shares of Veru from a “sell” rating to a “hold” rating in a research report on Wednesday, March 7th. Maxim Group initiated coverage on shares of Veru in a research report on Tuesday. They issued a “buy” rating for the company. HC Wainwright set a $5.00 price objective on shares of Veru and gave the stock a “buy” rating in a research report on Thursday, May 10th. Finally, Dawson James restated a “buy” rating on shares of Veru in a research report on Monday, June 25th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $4.17.

Veru traded up $0.02, hitting $1.95, during trading on Tuesday, reports. The company had a trading volume of 608,800 shares, compared to its average volume of 135,161. The company has a debt-to-equity ratio of 0.14, a current ratio of 1.53 and a quick ratio of 1.19. Veru has a 12 month low of $0.90 and a 12 month high of $3.00. The stock has a market capitalization of $108.10 million, a PE ratio of -7.80 and a beta of 0.66.

Veru (NASDAQ:VERU) last posted its quarterly earnings data on Wednesday, May 9th. The company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.02). Veru had a negative return on equity of 21.72% and a negative net margin of 87.78%. The company had revenue of $2.57 million during the quarter, compared to the consensus estimate of $7.60 million. equities analysts expect that Veru will post -0.18 earnings per share for the current fiscal year.

Veru Company Profile

Veru Inc operates as a urology and oncology biopharmaceutical company. The company operates through two segments, Commercial; and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation.

Insider Buying and Selling by Quarter for Veru (NASDAQ:VERU)

Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with's FREE daily email newsletter.